These are competitors to Visx along with Summit Technology and a number of companies in Europe. They all correct vision in a similar manner. None have LTK. Of the group, only B&L would be a potential acquirer. The others that could acquire are the large companies like Chiron who already own one of the European companies, Alcon, Allergan, and several others. Visx is also a potential acquirer.
While we will all make a quick buck if an acquisition would occur, I believe we would be cheated out of a lot of the potential SNRS has. (I have not taken a close look at the anti-takeover measures the company implemented a while back, but it looks like the stock price would be driven up to around $20. If anyone understands these measures and what will happen to the stock price in the event of a takeover, please comment.)
If a large company acquired SNRS, then all we get would be stock in that company (or worse, cash) and we would have to live with what ever their growth and price appreciation was. (If it was a Merck wouldn't be too bad, but it won't be.)
If it were a Visx, then we would get stock and SNRS would give a short term boost to their value. Then as the product rolled out, we would see a gradual rise, but it would be moderated by the rest of their business. SNRS on it's own will rise much more dramatically. |
